This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
INVANZ 1 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION — Description, Dosage, Side Effects | PillsCard
OTC
INVANZ 1 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION
INN: INVANZ
Data updated: 2026-04-11
Available in:
🇩🇪🇬🇧🇪🇸🇹🇷
Form
—
Dosage
—
Route
—
Storage
—
About This Product
Manufacturer
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
Merck Sharp & Dohme B.V. (ES)
Source
CIMA_ES
(
ARTG
)
INVANZ is indicated for the treatment of adult patients with moderate to severe infections caused by susceptible strains of microorganisms, which are suspected or proven to be resistant to all other antibiotics, or for patients unable to tolerate other antibiotics. INVANZ is also indicated for initial empiric therapy for the treatment of complicated intra-abdominal infections and acute pelvic infections including post-partum endomyometritis, septic abortion and post-surgical gynaecological infections. Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify the causative organisms and to determine their susceptibility to ertapenem. Therapy with INVANZ may be initiated empirically before the results of these tests are known; once these results become available, antimicrobial therapy should be adjusted accordingly.,INVANZ is indicated for the treatment of patients, aged 3 months or more, with moderate to severe infections (except meningitis, see PRECAUTIONS) caused by susceptible strains of micro-organisms which are suspected or proven to be resistant to all other antibiotics, or for patients unable to tolerate other antibiotics. INVANZ is also indicated for initial empiric therapy for the treatment of complicated intra-abdominal infections and acute pelvic infections including post-partum endomyometritis, septic abortion and post-surgical gynaecological infections. INVANZ is also indicated for Treatment of diabetic foot infections, which require parenteral antibiotic therapy and are caused by susceptible bacterial pathogens which are suspected or proven to be resistant to all other registered antibiotics, or for patients unable to tolerate other antibiotics. Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify the causative organisms and to determine their susceptibility to ertapenem. Therapy with INVANZ may be initiated empirically before the results of these tests are known; once these results become available, antimicrobial therapy should be adjusted accordingly.